Merit Medical Systems, Inc.  

(Public, NASDAQ:MMSI)   Watch this stock  
Find more results for MMSI
18.74
0.00 (0.00%)
Jun 24 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 15.47 - 26.42
Open     -
Vol / Avg. 0.00/208,204.00
Mkt cap 796.77M
P/E 36.21
Div/yield     -
EPS 0.52
Shares 44.31M
Beta 0.86
Inst. own 92%
Jul 21, 2016
Q2 2016 Merit Medical Systems Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
May 26, 2016
Merit Medical Systems Inc Annual Shareholders Meeting
May 23, 2016
Merit Medical Systems Inc at UBS Global Healthcare Conference
May 20, 2016
Merit Medical Systems Inc Annual Shareholders Meeting (Estimated)
Apr 28, 2016
Q1 2016 Merit Medical Systems Inc Earnings Call - Webcast
Apr 28, 2016
Q1 2016 Merit Medical Systems Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin 3.15% 4.39%
Operating margin 5.58% 6.92%
EBITD margin - 13.83%
Return on average assets 2.21% 3.12%
Return on average equity 3.72% 5.28%
Employees 3,754 -
CDP Score - -

Address

1600 W Merit Pkwy
SOUTH JORDAN, UT 84095-2416
United States - Map
+1-801-2531600 (Phone)
+1-801-2531652 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Merit Medical Systems, Inc. is a designer, developer, manufacturer and marketer of medical devices used in an array of interventional and diagnostic procedures. The Company operates in two segments: cardiovascular and endoscopy. Its cardiovascular segment consists of cardiology and radiology devices, which assist in diagnosing and treating coronary arterial disease, peripheral vascular disease and other non-vascular diseases; embolotherapeutic products, and cardiac rhythm management and electrophysiology (CRM/EP) devices. Its endoscopy segment consists of gastroenterology and pulmonology medical devices, which assist in the palliative treatment of expanding esophageal, tracheobronchial and biliary strictures caused by malignant tumors. Its products are used in various clinical areas, such as diagnostic and interventional cardiology; interventional radiology; vascular, general and thoracic surgery; interventional pulmonology; interventional nephrology; oncology, and pain management.

Officers and directors

Fred P. Lampropoulos Chairman of the Board, President, Chief Executive Officer
Age: 65
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Bernard Birkett Chief Financial Officer
Bio & Compensation  - Reuters
Ronald A. Frost Chief Operating Officer
Age: 53
Bio & Compensation  - Reuters
Kent W. Stanger Director
Age: 60
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
A. Scott Anderson Independent Director
Age: 68
Bio & Compensation  - Reuters
Richard W. Edelman Independent Director
Age: 74
Bio & Compensation  - Reuters
Nolan E. Karras Independent Director
Age: 70
Bio & Compensation  - Reuters
Franklin J. Miller Independent Director
Age: 74
Bio & Compensation  - Reuters